Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Dare Bioscience, Inc.

Get SEC filing alerts via email and in your feed for Dare Bioscience, Inc.

DARE

Dare Bioscience, Inc.

About Dare Bioscience, Inc.

Dare Bioscience Inc. develops innovative women’s health solutions, including prescription and compounded products for contraception, sexual health, menopause, and vaginal health. Its portfolio features FDA-approved XACIATO for bacterial vaginosis and pipeline candidates like Ovaprene, Sildenafil Cream, and DARE-HRT1, targeting unmet needs in fertility, VMS, and FSAD. The company leverages clinical data, strategic collaborations, and alternative pathways to bring evidence-based, first-in-category products to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Dare Bioscience, Inc.

1
1
Dare Bioscience, Inc. Daré Bioscience Reports 500% Revenue Growth but Faces $3M Net Loss in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Dare Bioscience, Inc. Dare Bioscience Reports 2025 Financial Results and Strategic Developments

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Dare Bioscience, Inc. Daré Bioscience Reports 95% Revenue Decline in Q3 2025, Plans New Product Launch

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Dare Bioscience, Inc. Daré Bioscience Reports Significant Revenue Decline and Strategic Shift in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Dare Bioscience, Inc. Daré Bioscience Reports 173% Revenue Increase in Q1 2025, Faces Continued Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Dare Bioscience, Inc. Dare Bioscience Reports $4.1 Million Net Loss for Fiscal Year 2024, Significant Improvement from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Dare Bioscience, Inc. Daré Bioscience Reports Significant Financial Decline and Turnaround in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments